Curia Invests $5.61 Million in Precision Fermentation Facility in León, Spain, Expanding Capacity to 58,000 Liters
Curia completes a €5M precision fermentation expansion in León, Spain, boosting capacity to 58,000 liters with new USP and DSP equipment and upgraded utili
Research Desk
Curia Global Inc. has finished a USD 5.61 million expansion at its León, Spain operations, a project that delivers a new precision fermentation facility and raises the site's capacity to 58,000 liters.
The contract research, development, and manufacturing organization (CDMO) announced the completion of the project from Albany, NY.
Equipment Installed Across USP and DSP
At the heart of the investment is a purpose-built facility housing fermentation, or upstream processing (USP), equipment alongside downstream processing (DSP) equipment.
According to the company, this combination enables optimized manufacturing flows and supports development and scale-up activities through capacity enablement and upgraded site utilities. The new equipment installations bring the facility's total capacity to 58,000 L.
Critical Utility Systems Brought Online
Beyond the production floor, the project also covered the installation of critical utility systems needed to fully support the new production building. Curia stated that these upgrades are intended to provide a reliable utility supply across production operations.
Jamie Grabowski, President of R&D at Curia, framed the work as part of the company's commitment to supporting customers with reliable, efficient manufacturing and flexible capacity as programs advance.
"By aligning our equipment footprint and upgrading essential utilities, we are building a strong foundation for sustained performance at León," Grabowski said.
What León Does for Curia's Customers
The León site specializes in biotechnology development, fermentation production, and downstream processing, serving customers across the pharmaceutical, cosmetic, agriculture, and food industries.
Curia characterized the expansion as a reflection of its continued focus on strengthening its manufacturing network, ensuring its sites are equipped to meet evolving customer needs through dependable operations and high standards of quality.
The Company Behind the Expansion
Curia is a CDMO with over 30 years of experience, operating an integrated network of more than 20 global sites staffed by 3,100 employees who partner with biopharmaceutical customers to bring therapies to market.
Its offerings cover small molecules, generic APIs, and biologics, spanning discovery through commercialization, with integrated regulatory, analytical, and sterile fill-finish capabilities.
The company's services extend across both drug substance and drug product manufacturing.
Tracked in the database
Biologics Contract Manufacturing Expansion · Europe
Biologics Contract Manufacturing Expansion
Europe
Chemical
10 November 2026
2 min read
Tagged
Also read
Biocon Secures European Commission Approval for Pertuzumab Biosimilar Pebrilzo in HER2-Positive Breast Cancer
Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany
LOTTE Biologics Signs First Commercial Manufacturing Agreement for Songdo Plant 1 in South Korea
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.